La consultation de suivi du THM. Conduite à tenir en cas de tumeur mammaire (clinique ou radiologique) et de microcalcifications. RPC Les femmes ménopausées du CNGOF et du GEMVi

Mathelin, Carole; Molière, Sébastien

doi:10.1016/j.gofs.2021.03.026

Cited by 1 publication

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ця резолюція була розроблена експертами з урахуванням консолідованих міжнародних рекомендацій щодо МГТ [7,[9][10][11][12][13][14][15] і результатів ключових наукових досліджень [16][17][18][19][20][21][22][23].…”

unclassified

“…(2021) за результатами ретроспективного когортного дослідження за участю 51 571 жінки віком 40-89 років без ризику тромбозів Рисунок 4. Алгоритм ухвалення рішення щодо старту або продовження МГТ у жінок із виявленими пухлиноподібними новоутвореннями молочної залози[15]…”

unclassified

See 1 more Smart Citation

Resolution of the III International menopause expert forum

2022

View full text Add to dashboard Cite

The III International Menopause Expert Forum took place on November 24, 2021. The working group of the expert council included leading experts in endocrine gynaecology from Belarus, Armenia, Georgia, Kazakhstan, Kyrgyzstan, Uzbekistan, and Ukraine.To date, menopause hormone therapy (MHT) initiated during the “therapeutic window of opportunity” has proved to have a protective effect against various age-associated diseases. Despite this, the percentage of women using MHT remains low and, for example, in Ukraine and Kazakhstan, equals nearly 2%. However, only one in four of these women have been using MHT for more than a year. The main reasons for such low percentage of women using MHT are as follows:1. Low patient adherence to MHT (due to misunderstanding of the menopause factors, menopause symptoms, treatments, hormonophobia, poor communication with healthcare professionals etc.).2. Healthcare professional’s vigilance due to the possible risks associated with MHT (breast cancer, venous thromboembolism, cardiovascular diseases etc.).3. Healthcare professionals face difficulties during the MHT prescription or subsequent patient management (unplanned haemorrhages, concomitant pathologies in a woman, i.e. fibroids, varicose veins, arterial hypertension etc.). Aiming to improve medical care for menopausal women, experts attending the Forum focused on the latest data on the risks of breast cancer and venous thromboembolism, MHT effect on the risk of coronary heart disease and arterial hypertension, the potential of prescribing MHT to patients with uterine myoma and on increasing treatment adherence.

show abstract

unclassified

Resolution of the III International menopause expert forum

2022

View full text Add to dashboard Cite

show abstract

La consultation de suivi du THM. Conduite à tenir en cas de tumeur mammaire (clinique ou radiologique) et de microcalcifications. RPC Les femmes ménopausées du CNGOF et du GEMVi

Cited by 1 publication

References 34 publications

Resolution of the III International menopause expert forum

Resolution of the III International menopause expert forum

Contact Info

Product

Resources

About